



www.figo.org

Contents lists available at ScienceDirect

International Journal of Gynecology and Obstetrics

journal homepage: www.elsevier.com/locate/ijgo

REPRODUCTIVE HEALTH

Cancer of the cervix: Early detection and cost-effective solutions

Lynette Denny^{a,*}, Walter Prendiville^b^a University of Cape Town/Groote Schuur Hospital, Cape Town, South Africa^b International Agency for Research on Cancer, 150 Cours Albert Thomas, Lyon, France

ARTICLE INFO

Keywords:

Cervical cancer
 Cost-effectiveness
 HPV
 HPV DNA testing
 Secondary prevention
 Visual inspection with acetic acid

ABSTRACT

Cervical cancer is known to be a preventable disease through the detection of cervical cancer precursors, historically using cytology of the cervix as the primary screening test. Over 85% of cervical cancer cases and deaths occur in low-resource countries. Alternatives to cytology have been investigated with the strongest possibilities being visual inspection with acetic acid (VIA) and HPV DNA testing. HPV DNA testing has been shown in randomized trials to be significantly more sensitive for the detection of cervical cancer precursors than either cytology or VIA. In this paper we argue that prevention really does cost less than cure, or that prevention and treatment of cancer costs less than no prevention, in effect just treatment, of cancer. The true cost savings of prevention will include a more difficult assessment of the socioeconomic savings associated with longer, healthier lives for women in their prime who have a major role in supporting their families.

© 2015 Published by Elsevier Ireland Ltd. on behalf of International Federation of Gynecology and Obstetrics. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

1. Introduction

Globally there were 14 million new cases of cancer and 8 million cancer-related deaths in 2012 [1]. This database reveals that breast and cervical cancer are among the most common incident sites of cancer in women, representing over one-third of the total. Among women, breast cancer has a substantially higher incidence (43.3 per 100 000) than any other cancer, representing 25.2% of all cancers diagnosed in females [2].

In Sub-Saharan Africa, the incidence of cervical cancer is equivalent to breast cancer, each constituting approximately one-quarter of the total burden (Figs. 1 and 2). The incidence and mortality rates for cervical cancer in Sub-Saharan Africa are 34.8 and 22.5 per 100 000 respectively—the highest of any world region. In Sub-Saharan Africa, cervical cancer is the most common cause of cancer death in women (23.2% of the total) [3]. Cancer of the breast and cervix kill more women than any other forms of cancer in all low-resource regions of the world [4]. Sixty-two percent ($n = 57\,318$) of women in Sub-Saharan Africa diagnosed with cervical cancer died compared with 50% ($n = 47\,583$) of women with breast cancer [5]. Over 85% of incident cases and deaths from cervical cancer occur in low-resource countries where the initiation and/or maintenance of cervical cancer screening programs have proved impossible [5]. Weak healthcare systems, lack of financial and human resources, competing health needs, war and civil strife, and widespread poverty have prevented many governments from supporting cervical cancer prevention programs.

2. Secondary prevention

While historically cervical cytology has been the mainstay of secondary prevention and, where successfully implemented, has had a major impact on reducing the incidence of and mortality from cervical cancer, the demands of the test are too complex for many low-resource countries. The past 15 years has seen a surge in studies designed to find alternative tests to cytology, specifically to allow point-of-care testing to enable women to be screened and treated in a single visit, without the necessity for complex and expensive laboratory investigations as well as colposcopy and histological examination.

In low-resource countries, these studies have focused mainly on using visual inspection with acetic acid (VIA) and testing for DNA of high-risk types of HPV, so-called HPV DNA testing. Cross-sectional studies of VIA initially were quite reassuring and most studies demonstrated relatively high sensitivity, but low specificity and positive predictive value. Sauvaget et al. [6] performed a meta-analysis of 26 studies of VIA performed in low- and middle-income countries. Overall, VIA had a pooled sensitivity of 80%, specificity of 92%, a positive predictive value of 10%, and a negative predictive value of 99% for the detection of cervical intraepithelial neoplasia (CIN) 2+. In all of the studies, VIA was performed in asymptomatic women who all underwent confirmatory testing; however, there were inconsistencies among the studies.

In longitudinal studies however, Denny et al. [7] in a randomized controlled trial of 6555 unscreened women aged 35–65 years of age showed that the sensitivity of VIA for high-grade precursors was around 48% when women were followed for 36 months. By contrast the sensitivity of HPV DNA testing for high-risk types (using Hybrid Capture 2; Qiagen, Gaithersburg, MD, USA) was consistently higher than either

* Corresponding author at: H45, Old Main Building, Groote Schuur Hospital, Observatory, 7925, Cape Town, South Africa. Tel.: +27 21 404 4485; fax: +27 21 4486921. E-mail address: lynette.denny@uct.ac.za (L. Denny).




Fig. 1. Sub-Saharan Africa. Estimated age-standardized (World) cancer incidence and mortality rates (ASR) per 100 000, by major sites in men and women, 2012. Reproduced with permission from: Forman D, Bray F, Brewster DH, Gombe Mbalawa C, Kohler B, Pineros M, et al., eds. Cancer incidence in five continents, Vol. X (electronic version). Lyon: IARC; 2013. Accessed 24 September 24, 2014.

cytology or VIA and had a sensitivity of 86% for high-grade cervical cancer precursors over a 36-month follow-up period. Further, for every 100 women screened, the HPV screen-and-treat strategy eliminated 4.1 cases of CIN 2 or greater compared with VIA-and-treat, which eliminated 1.8 cases.

In another landmark study, Sankaranarayanan et al. [8] performed a cluster randomized trial of 131 746 women aged 30–59 years who were randomly assigned to one of four groups: HPV testing; cytological testing; VIA; or standard of care that involved no screening as the control group. The incidence rate of cervical cancer stage 2 or higher and death rates from cervical cancer were significantly higher in the cytological, VIA, and control groups compared with the HPV testing group. Furthermore, the age-standardized incidence rate of invasive cancer among women who had negative test results on cytological or VIA testing was more than four times greater than the rate among HPV-negative women.

These data suggest that primary screening with HPV DNA, followed by treatment will be associated with a significant reduction in cervical cancer and cervical cancer precursors. HPV DNA testing is a

Table 1
Cost of treating cervical cancer among Medicaid beneficiaries in North Carolina, USA.^a

	Stage 0	Stage I	Stage II–IV A	Stage IV B
12-month cost, US \$	6347	32 255	46 681	83 494

^a Source: Subramanian et al. [15].

laboratory-based test and current commercially available tests are not affordable in low-resource countries. The ideal test for HPV DNA detection would provide a result at the time of examination and screening—a point-of-care test. Such a test has recently become available, the GeneXpert test (Cepheid; Sunnyvale, CA, USA), which can provide a result within one hour. Clinical trials in a screen-and-treat setting are soon to be established.

There is currently a great deal of research on using HPV DNA testing as either a primary screen or as an adjunct to cytology in women over 30 years of age. Ronco et al. [9] reported on 176 464 women aged 20–64 years who participated in four randomized trials in Sweden, the Netherlands, England, and Italy. Women were randomly assigned to HPV-based (experimental arm) or cytology-based (control arm) screening and were followed for a median of 6.5 years during which 107 invasive cervical cancers were identified. Detection of invasive cancer was similar in the two arms in the first 2.5 years of follow-up but was significantly lower in the HPV screening arm. Further, the cumulative incidence of invasive cervical cancer in women with a negative screening test at entry was double in the control versus the experimental arm. These four trials showed that HPV testing provides 60%–70% greater protection against invasive cervical cancer compared with cytology and the authors recommend initiation of HPV-based screening from age 30 years and to extend the screening intervals to 5 years.

While many studies have focused on the characteristics of screening tests, the programmatic issues often pose the strongest barriers to successful screening. WHO began a demonstration project called “Prevention of cervical cancer through screening using VIA and treatment with cryotherapy” [10], which recruited 19 579 women from September 2005 to May 2009 from six countries in Africa (Madagascar, Malawi, Nigeria, Uganda, Tanzania, and Zambia). Overall, 11.5% (n = 1980) of women screened were VIA positive and 1.7% (n = 326) were found to be suspicious for cancer. Of the 1980 women with positive VIA, 87.7% (n = 1737) were eligible for cryotherapy and 60.9% (n = 1058) underwent cryotherapy, 34.6% (n = 601) were lost to follow-up, and 4.5% (n = 78) did not undergo cryotherapy.




Fig. 2. Sub-Saharan Africa. Estimated cancer five-year prevalence proportions by major sites, in both sexes combined, 2012. Reproduced with permission from: Bray F, Ren JS, Masuyer E, Ferlay J. Global estimates of cancer prevalence for 27 sites in the adult population in 2008. Int J Cancer 2013;132(5):1133–45.

Download English Version:

<https://daneshyari.com/en/article/3951649>

Download Persian Version:

<https://daneshyari.com/article/3951649>

[Daneshyari.com](https://daneshyari.com)